{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:20:51Z","timestamp":1787746851818,"version":"build-2784847793"},"reference-count":244,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Circulating tumor DNA (ctDNA), a core component of liquid biopsy, demonstrates significant potential in the field of neoadjuvant therapy for solid tumors. This review systematically examines the role of ctDNA across the pre-, intra-, and post-neoadjuvant treatment phases, with a focus on its value in predicting therapeutic efficacy, assessing early treatment response, detecting minimal residual disease (MRD), and monitoring for recurrence. By synthesizing the latest clinical research data and advancements in molecular detection technologies, this article aims to elucidate how ctDNA is facilitating a shift towards more precise, dynamic, and individualized paradigms in neoadjuvant therapy for solid tumors. Furthermore, it analyzes the current challenges and future directions for integrating ctDNA analysis into clinical practice to optimize patient management and outcomes. Throughout, clinically validated applications are explicitly distinguished from those that remain investigational, and key unresolved questions are highlighted.<\/jats:p>","DOI":"10.3389\/fonc.2026.1909934","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:43:06Z","timestamp":1787744586000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating tumor DNA in neoadjuvant therapy for solid tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Xueqin","family":"Huang","sequence":"first","affiliation":[{"name":"Hemodialysis Center, Department of Nephrology, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China School of Public Health and West China Fourth Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12672-026-04495-2","article-title":"Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting","volume":"17","author":"Ahmed","year":"2026","journal-title":"Discov Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-021-00559-x","article-title":"Commercial ctDNA assays for minimal residual disease detection of solid tumors","volume":"25","author":"Chen","year":"2021","journal-title":"Mol Diagn Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2023.2274123","article-title":"Clinical application of molecular residual disease detection by circulation tumor DNA in solid cancers and a comparison of technologies: review article","volume":"24","author":"Dong","year":"2023","journal-title":"Cancer Biol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-023-00670-1","article-title":"Personalized cancer monitoring assay for the detection of ctDNA in patients with solid tumors","volume":"27","author":"Zhao","year":"2023","journal-title":"Mol Diagn Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70483","article-title":"Personalized and tumor informed circulating tumor DNA assay for molecular residual disease monitoring of solid Malignancies","volume":"6","author":"Liu","year":"2025","journal-title":"MedComm"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03216-y","article-title":"Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma","volume":"31","author":"Black","year":"2025","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"103645","DOI":"10.1016\/j.jtho.2026.103645","article-title":"Identifying patients with high-risk stage I NSCLC using a tumor-informed plasma ctDNA assay","volume":"21","author":"Feng","year":"2026","journal-title":"J Thorac Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.4457","article-title":"Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review","volume":"8","author":"Krebs","year":"2022","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8703","DOI":"10.3390\/ijms25168703","article-title":"Recent technologies towards diagnostic and therapeutic applications of circulating nucleic acids in colorectal cancers","volume":"25","author":"Chung","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8122","DOI":"10.1038\/s41598-020-64822-7","article-title":"Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS z480 and BEAMing","volume":"10","author":"Vessies","year":"2020","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101589","article-title":"Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer","volume":"27","author":"Visser","year":"2023","journal-title":"Transl Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3200","article-title":"Timing of ctDNA analysis aimed at guiding adjuvant treatment in colorectal cancer","volume":"31","author":"Henriksen","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3892\/or.2023.8543","article-title":"Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (review)","volume":"49","author":"Chen","year":"2023","journal-title":"Oncol Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216505","article-title":"Comparison of tumor-informed and tumor-na\u00efve sequencing assays for ctDNA detection in breast cancer","volume":"15","author":"Santonja","year":"2023","journal-title":"EMBO Mol Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3390\/ijms27031569","article-title":"Circulating tumor DNA in melanoma: Advances in detection, clinical applications, and integration with emerging technologies","volume":"27","author":"Charbel","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20200419-00197","article-title":"The role of circulating tumor DNA in the diagnosis and prognosis of hepatocellular carcinoma","volume":"30","author":"Fan","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8851","DOI":"10.1038\/s41467-024-53145-0","article-title":"Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp","volume":"15","author":"Rodrigues","year":"2024","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1038\/s41598-025-90013-3","article-title":"Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring","volume":"15","author":"Ye","year":"2025","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.70161","article-title":"Detection of circulating tumor DNA in colorectal cancer patients using a methylation-specific droplet digital PCR multiplex","volume":"20","author":"do Canto","year":"2026","journal-title":"Mol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0134","article-title":"Droplet digital PCR assay for detection and monitoring of universally methylated ctDNA in patients with sarcoma","volume":"31","author":"Ashton","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13058-025-02077-8","article-title":"A comparative study of four cell-free DNA assays for detecting circulating tumor DNA in early breast cancer","volume":"27","author":"Mulder","year":"2025","journal-title":"Breast Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2023.115694","article-title":"Fast, sensitive, and specific multiplexed single-molecule detection of circulating tumor DNA","volume":"242","author":"Shin","year":"2023","journal-title":"Biosens Bioelectron"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1039\/d5ay01518a","article-title":"Exonuclease III-assisted gold nanoparticle conjugated DNA walker for sensitive and specific detection of circulating tumor DNA","volume":"17","author":"Yao","year":"2025","journal-title":"Anal Methods"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105286","article-title":"Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer","volume":"10","author":"Elliott","year":"2025","journal-title":"ESMO Open"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2144\/btn-2020-0045","article-title":"Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay","volume":"69","author":"Fettke","year":"2020","journal-title":"Biotechniques"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/00365513.2020.1821394","article-title":"Performance comparison of commercial kits for isolating and detecting circulating tumor DNA","volume":"81","author":"Wang","year":"2021","journal-title":"Scand J Clin Lab Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.811291","article-title":"Sensitive quantification of cell-free tumor DNA for early detection of recurrence in colorectal cancer","volume":"12","author":"Stasik","year":"2021","journal-title":"Front Genet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.05.014","article-title":"Whole-genome mutational analysis for tumor-informed detection of circulating tumor DNA in patients with urothelial carcinoma","volume":"86","author":"Nordentoft","year":"2024","journal-title":"Eur Urol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41698-025-01147-6","article-title":"Patient-specific sequencing panels enable sensitive circulating tumor DNA analysis in rhabdomyosarcoma independent of genetic profile","volume":"9","author":"Rahmqvist","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3145","article-title":"Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple-negative breast cancer","volume":"31","author":"Ademuyiwa","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/cancers16010082","article-title":"A novel tissue-free method to estimate tumor-derived cell-free DNA quantity using tumor methylation patterns","volume":"16","author":"Melton","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvac020","article-title":"Highly specific droplet-digital PCR detection of universally methylated circulating tumor DNA in endometrial carcinoma","volume":"68","author":"Beinse","year":"2022","journal-title":"Clin Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100301","article-title":"International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors","volume":"8","author":"Fusco","year":"2025","journal-title":"J Liq Biopsy"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa164","article-title":"Generic protocols for the analytical validation of next-generation sequencing-based ctDNA assays: A joint consensus recommendation of the BloodPAC\u2019s Analytical Variables Working Group","volume":"66","author":"Godsey","year":"2020","journal-title":"Clin Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3321","article-title":"Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation","volume":"30","author":"Rolfo","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102390","article-title":"Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis","volume":"9","author":"Nader-Marta","year":"2024","journal-title":"ESMO Open"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.03.002","article-title":"Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy","volume":"7","author":"Ben-David","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230622","article-title":"Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation","volume":"15","author":"Cho","year":"2020","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2023.100004","article-title":"Relationship of tumor fraction in circulating tumor DNA with prognosis in patients with advanced urothelial cancer","volume":"3","author":"Miron","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S573159","article-title":"Correlation analysis between circulating tumor DNA and prognosis in patients with hepatocellular carcinoma","volume":"18","author":"Ma","year":"2026","journal-title":"Cancer Manag Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00384-024-04785-7","article-title":"Circulating tumor DNA as a predictive biomarker for treatment response and survival in metastatic colorectal cancer","volume":"39","author":"Kou","year":"2024","journal-title":"Int J Colorectal Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13755","article-title":"Circulating tumor DNA (ctDNA) trajectories predict survival in trifluridine\/tipiracil-treated metastatic colorectal cancer patients","volume":"19","author":"Unseld","year":"2025","journal-title":"Mol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17036-y","article-title":"Molecular KRAS ctDNA predicts metastases and survival in pancreatic cancer: A prospective cohort study","volume":"32","author":"Leiting","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.21873\/cgp.20423","article-title":"Preoperative ctDNA levels are associated with poor overall survival in patients with ovarian cancer","volume":"20","author":"Dobilas","year":"2023","journal-title":"Cancer Genomics Proteomics"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15227","article-title":"Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA","volume":"36","author":"Hirai","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2020.1837928","article-title":"TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma","volume":"55","author":"Oversoe","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0234","article-title":"ctDNA detected after neoadjuvant therapy for HER2-positive breast cancer is associated with inferior outcomes and may inform adjuvant therapy","volume":"6","author":"Lin","year":"2026","journal-title":"Cancer Res Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.12.10","article-title":"Presence of allele frequency heterogeneity defined by ctDNA profiling predicts unfavorable overall survival of NSCLC","volume":"8","author":"Liu","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0760","article-title":"Clinical applications of circulating tumor DNA in monitoring breast cancer drug resistance","volume":"16","author":"Liu","year":"2020","journal-title":"Future Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3390\/diagnostics12081799","article-title":"Applications of liquid biopsies in non-small-cell lung cancer","volume":"12","author":"Pesta","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.3390\/cancers14133275","article-title":"Circulating tumor DNA-based genomic profiling assays in adult solid tumors for precision oncology: Recent advancements and future challenges","volume":"14","author":"Chan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107359","article-title":"Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience","volume":"185","author":"Porta","year":"2023","journal-title":"Lung Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.3390\/cancers16132432","article-title":"Decoding the dynamics of circulating tumor DNA in liquid biopsies","volume":"16","author":"Turabi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14737140.2025.2575827","article-title":"Harnessing genomic profiling for improved urothelial cancer outcomes","volume":"26","author":"Yu","year":"2026","journal-title":"Expert Rev Anticancer Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13046-024-03153-1","article-title":"Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy","volume":"43","author":"Chan","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.3390\/cancers16233919","article-title":"Circulating tumor DNA in early and metastatic breast cance-current role and what is coming next","volume":"16","author":"Tegeler","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/curroncol32120692","article-title":"Identification of actionable mutations in metastatic castration-resistant prostate cancer through circulating tumor DNA: Are we there yet","volume":"32","author":"Tao","year":"2025","journal-title":"Curr Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: Current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70943","article-title":"Performance comparison of droplet digital PCR and next-generation sequencing for circulating tumor DNA detection in non-metastatic rectal cancer","volume":"14","author":"Szeto","year":"2025","journal-title":"Cancer Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"9945","DOI":"10.1038\/s41467-025-65432-5","article-title":"Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors","volume":"16","author":"Magbanua","year":"2025","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-100223-090016","article-title":"Circulating tumor DNA: A pan-cancer biomarker in solid tumors with prognostic and predictive value","volume":"76","author":"Hitchen","year":"2025","journal-title":"Annu Rev Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1186\/s12885-024-12689-6","article-title":"Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13604-2","article-title":"Early circulating tumor DNA dynamics predict neoadjuvant therapy response and recurrence in colorectal liver metastases: A prospective study","volume":"30","author":"Wang","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0741","article-title":"Circulating tumor DNA kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)","volume":"28","author":"Mack","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1038\/s41467-025-56658-4","article-title":"Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay","volume":"16","author":"Elliott","year":"2025","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.03.019","article-title":"Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"36","author":"Valenza","year":"2025","journal-title":"Ann Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/1878-0261.13349","article-title":"Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab","volume":"17","author":"Kansara","year":"2023","journal-title":"Mol Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/cells14171312","article-title":"Utility and future perspectives of circulating tumor DNA analysis in non-small cell lung cancer patients in the era of perioperative chemo-immunotherapy","volume":"14","author":"Ohara","year":"2025","journal-title":"Cells"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.116198","article-title":"Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses","volume":"234","author":"Guo","year":"2025","journal-title":"Eur J Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3774","article-title":"Dynamic ctDNA monitoring guides early treatment intensification in locally advanced rectal cancer undergoing neoadjuvant chemotherapy","volume":"32","author":"Shen","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003741","article-title":"Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study","volume":"18","author":"Wang","year":"2021","journal-title":"PloS Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e004688","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy","volume":"10","author":"Hwang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/cancers18050815","article-title":"Circulating tumour DNA after neoadjuvant therapy in non-metastatic colon cancer: A systematic review and implications for surgical decision-making","volume":"18","author":"Salama","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: A phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1038\/s41467-025-57988-z","article-title":"Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad336","article-title":"Circulating tumor DNA to predict radiographic and pathologic response to total neoadjuvant therapy in locally advanced rectal cancer","volume":"29","author":"Alden","year":"2024","journal-title":"Oncologist"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.3390\/cancers17152560","article-title":"Circulating tumor DNA detects minimal residual disease in patients with locally advanced rectal cancer after total neoadjuvant therapy","volume":"17","author":"Kim","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217574","article-title":"The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients","volume":"616","author":"Zeng","year":"2025","journal-title":"Cancer Lett"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03588-5","article-title":"Clinical application of circulating tumor DNA in breast cancer","volume":"147","author":"Chan","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2024.100284","article-title":"ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients","volume":"7","author":"Bharde","year":"2025","journal-title":"J Liq Biopsy"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000001168","article-title":"Liquid biopsy in breast cancer: Promises and challenges","volume":"37","author":"Loizidis","year":"2025","journal-title":"Curr Opin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00274","article-title":"Current clinical utility of circulating tumor DNA testing in breast cancer: A practical approach","volume":"20","author":"Xi","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1696","article-title":"Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study","volume":"29","author":"Vidal","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100853","article-title":"Longitudinal circulating tumor DNA-guided resistance analysis during second-line osimertinib treatment","volume":"6","author":"van der Wel","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B86","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/cancers16050940","article-title":"ctDNA for the evaluation and management of EGFR-mutant non-small cell lung cancer","volume":"16","author":"Desai","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae041","article-title":"Plasma ctDNA enables early detection of temozolomide resistance mutations in glioma","volume":"6","author":"Jones","year":"2024","journal-title":"Neuro-Oncol Adv"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2998","article-title":"Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer","volume":"29","author":"Tolmeijer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1096","article-title":"Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer","volume":"30","author":"Sweeney","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3390\/cancers13081826","article-title":"Circulating tumor DNA early kinetics predict response of metastatic melanoma to anti-PD1 immunotherapy: Validation study","volume":"13","author":"Herbreteau","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000521841","article-title":"Clinical utility of liquid biopsy to identify genomic heterogeneity and secondary cancer diagnoses: A case report","volume":"15","author":"Hemenway","year":"2022","journal-title":"Case Rep Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"8594","DOI":"10.3390\/ijms25168594","article-title":"Liquid biopsy in the clinical management of cancers","volume":"25","author":"Ho","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi8618","article-title":"Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges","volume":"8","author":"Sanz-Garcia","year":"2022","journal-title":"Sci Adv"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02934","article-title":"The pathologic response evaluation and detection in circulating tumor-DNA study: Ultrasensitive circulating tumor-DNA assessment of breast cancer minimal residual disease","volume":"44","author":"Hunter","year":"2026","journal-title":"J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002341","article-title":"TP53-centric ctDNA complements PET\/CT for non-invasive assessment of pathological complete response and survival after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: A prospective cohort study","volume":"111","author":"Yang","year":"2025","journal-title":"Int J Surg"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217442","article-title":"Longitudinal circulating tumor DNA monitoring in predicting response to short-course radiotherapy followed by neoadjuvant chemotherapy and camrelizumab in locally advanced rectal cancer: Data from a phase III clinical trial (UNION)","volume":"611","author":"Lin","year":"2025","journal-title":"Cancer Lett"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000003950","article-title":"Brave new world: Analysis of early clinical experience with molecular sequencing in the treatment of rectal cancer","volume":"68","author":"Yee","year":"2025","journal-title":"Dis Colon Rectum"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102334","article-title":"ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00288","article-title":"Circulating tumor DNA as a prognostic biomarker for recurrence in patients with locoregional esophagogastric cancers with a pathologic complete response","volume":"8","author":"Lander","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3679","article-title":"Heterogeneity of residual disease after neoadjuvant systemic therapy in breast cancer: A review","volume":"10","author":"Tarantino","year":"2024","journal-title":"JAMA Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-021-01089-z","article-title":"Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer","volume":"14","author":"Chen","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2022.2033831","article-title":"Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: Current status and future perspectives","volume":"61","author":"Merk","year":"2022","journal-title":"Acta Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuroe.2025.501717","article-title":"Circulating tumor DNA in muscle-invasive bladder cancer: A systematic review","volume":"49","author":"Grosso","year":"2025","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3390\/cancers17121908","article-title":"Circulating tumor DNA in muscle-invasive bladder cancer: Implications for prognosis and treatment personalization","volume":"17","author":"Katsimperis","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: Circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1172108","article-title":"Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: A systematic review","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Genet"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02300-3","article-title":"Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer","volume":"129","author":"Ryoo","year":"2023","journal-title":"Br J Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1897","article-title":"Personalized MRD assessment in perisurgical ctDNA for prognostic prediction in hepatocellular carcinoma","volume":"31","author":"Hu","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.736769","article-title":"Circulating tumor DNA as a predictive marker of recurrence for patients with stage II-III breast cancer treated with neoadjuvant therapy","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"B111","article-title":"Current status of ctDNA-based MRD testing in breast cancer","volume":"52","author":"Ozaki","year":"2025","journal-title":"Gan To Kagaku Ryoho"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16926","article-title":"Clinical utility of tumour-informed circulating tumour DNA in patients with testicular cancer","volume":"136","author":"Ben-David","year":"2025","journal-title":"BJU Int"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006887","article-title":"Real-world monitoring of ctDNA reliably predicts cancer recurrence and treatment efficacy in patients with resected stages I-III colon cancer","author":"Cohen","year":"2025","journal-title":"Ann Surg"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2021.11.001","article-title":"Liquid biopsies for residual disease and recurrence","volume":"2","author":"Wan","year":"2021","journal-title":"Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1159\/000544838","article-title":"Will minimal residual disease monitoring be part of routine surveillance","volume":"48","author":"Pfister","year":"2025","journal-title":"Oncol Res Treat"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2024.12.002","article-title":"Liquid biopsy approaches to capture minimal residual disease and therapy response in patients with early stage cancers","volume":"399","author":"Landon","year":"2026","journal-title":"Int Rev Cell Mol Biol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1651","article-title":"Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay","volume":"30","author":"Nakamura","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"5364","DOI":"10.3390\/cancers13215364","article-title":"Liquid biopsy to detect minimal residual disease: Methodology and impact","volume":"13","author":"Honor\u00e9","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12916-023-02849-z","article-title":"Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: A meta-analysis","volume":"21","author":"Zhong","year":"2023","journal-title":"BMC Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3472","article-title":"Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer","volume":"31","author":"Elliott","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70286","article-title":"Minimal residual disease in solid tumors: Clinical applications and future directions","volume":"132","author":"Abdo","year":"2026","journal-title":"Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07357907.2026.2654136","article-title":"Practice-changing trials in gastrointestinal cancers at ASCO 2025: A critical review and clinical context","volume":"44","author":"Ismaili","year":"2026","journal-title":"Cancer Invest"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3390\/cancers18061014","article-title":"Liquid biopsy in gastrointestinal cancers: Circulating tumor DNA for molecular residual disease assessment and early treatment monitoring","volume":"18","author":"Safiejko","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.62347\/QOBT7285","article-title":"Hypermethylated SHOX2 in circulating cell-free DNA post renal cell carcinoma surgery as TNM-independent biomarker for recurrence risk","volume":"16","author":"B\u00fcttner","year":"2024","journal-title":"Am J Transl Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2024.11.002","article-title":"Emergence of circulating tumor DNA as a precision biomarker in lung cancer radiation oncology and beyond","volume":"39","author":"Hashmi","year":"2025","journal-title":"Hematol Oncol Clin North Am"},{"key":"B127","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/cancers18050754","article-title":"Circulating tumor DNA-based assessment of minimal residual disease in colorectal cancer: Prognostic and predictive implications","volume":"18","author":"Ozluk","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2024.0146","article-title":"Integration of liquid biopsy for optimal management of non-small cell lung cancer","volume":"88","author":"Oya","year":"2025","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-942","article-title":"Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: A narrative review","volume":"14","author":"Wang","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.3390\/cancers14133078","article-title":"Finding Waldo: The evolving paradigm of circulating tumor DNA (ctDNA)-guided minimal residual disease (MRD) assessment in colorectal cancer (CRC)","volume":"14","author":"Chakrabarti","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.48095\/ccko202532","article-title":"Importance of circulating tumor DNA in colorectal cancer","volume":"38","author":"Tolm\u00e1\u010di","year":"2025","journal-title":"Klin Onkol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/cancers13020346","article-title":"ctDNA and adjuvant therapy for colorectal cancer: Time to re-invent our treatment paradigm","volume":"13","author":"Naidoo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B133","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.3390\/cancers17223692","article-title":"Circulating tumor DNA (ctDNA) in gastroesophageal adenocarcinoma (GEA): Evidence and emerging applications","volume":"17","author":"Sahwan","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.70139","article-title":"DNA-based liquid biopsy for evaluating surgical and postsurgical outcomes in gynecologic Malignancies: A systematic review","volume":"40","author":"Yavari","year":"2026","journal-title":"J Clin Lab Anal"},{"key":"B135","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.3390\/cancers13122869","article-title":"ctDNA to guide adjuvant therapy in localized colorectal cancer (CRC)","volume":"13","author":"Masfarr\u00e9","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: A prospective multicenter cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102519","article-title":"Clinical applications of cell-free DNA-based liquid biopsy analysis","volume":"61","author":"Yazaki","year":"2025","journal-title":"Transl Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.46883\/2022.25920976","article-title":"Minimal residual disease-directed adjuvant therapy for patients with early-stage colon cancer: CIRCULATE-US","volume":"36","author":"Sahin","year":"2022","journal-title":"Oncol (Williston Park)"},{"key":"B139","doi-asserted-by":"publisher","first-page":"102411","DOI":"10.1016\/j.gassur.2026.102411","article-title":"The role of ctDNA in precision adjuvant therapy for colorectal cancer: A scoping review","volume":"30","author":"Jiang","year":"","journal-title":"J Gastrointest Surg"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114159","article-title":"A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: The importance of trial design","volume":"207","author":"Verschoor","year":"2024","journal-title":"Eur J Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16556","article-title":"Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes","volume":"135","author":"Ben-David","year":"2025","journal-title":"BJU Int"},{"key":"B142","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.3390\/cancers12102808","article-title":"The promise of circulating tumor DNA (ctDNA) in the management of early-stage colon cancer: A critical review","volume":"12","author":"Chakrabarti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B143","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12885-023-10699-4","article-title":"ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: A multi-centre, prospective, randomised control trial (TRACC Part C)","volume":"23","author":"Slater","year":"2023","journal-title":"BMC Cancer"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2589","article-title":"Early detection of molecular residual disease and risk stratification for children with acute myeloid leukemia via circulating tumor DNA","volume":"30","author":"Liu","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_349143","article-title":"Circulating tumor DNA: An emerging tool in gastrointestinal cancers","volume":"42","author":"Alese","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B146","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41419-020-2531-z","article-title":"Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Cell Death Dis"},{"key":"B147","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10549-024-07508-2","article-title":"Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer","volume":"209","author":"Garcia-Murillas","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00908","article-title":"Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer","volume":"40","author":"Lipsyc-Sharf","year":"2022","journal-title":"J Clin Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.12.026","article-title":"Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study","volume":"163","author":"\u00d8gaard","year":"2022","journal-title":"Eur J Cancer"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01716-7","article-title":"Liquid BIOpsy for MiNimal RESidual DiSease detection in head and neck squamous cell carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma","volume":"126","author":"Flach","year":"2022","journal-title":"Br J Cancer"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104534","article-title":"Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN)","volume":"10","author":"Honor\u00e9","year":"2025","journal-title":"ESMO Open"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004849","article-title":"Early detection of metastatic progression by circulating tumor DNA in patients undergoing bladder-preserving trimodality therapy","volume":"215","author":"Zhao","year":"2026","journal-title":"J Urol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1253629","article-title":"ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy","volume":"13","author":"Lebow","year":"2023","journal-title":"Front Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.10.032","article-title":"Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management","volume":"94","author":"Akaike","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4153","article-title":"Early detection of metastatic uveal melanoma by the analysis of tumor-specific mutations in cell-free plasma DNA","volume":"10","author":"Le Guin","year":"2021","journal-title":"Cancer Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03066-z","article-title":"Liquid biopsy for the assessment of adrenal cancer heterogeneity: where do we stand","volume":"77","author":"Perge","year":"2022","journal-title":"Endocrine"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100762","article-title":"Clinical significance of perioperative minimal residual disease detected by circulating tumor DNA in patients with lung cancer with a long follow-up data: An exploratory study","volume":"6","author":"Ohara","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70242","article-title":"Circulating tumor DNA informs clinical practice in patients with recurrent\/metastatic gastroesophageal cancers","volume":"132","author":"Mehta","year":"2026","journal-title":"Cancer"},{"key":"B159","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1038\/s41467-026-69984-y","article-title":"Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma","volume":"17","author":"Romesser","year":"2026","journal-title":"Nat Commun"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00734","article-title":"Circulating tumor DNA in urothelial cancer: Practical applications in oncology clinic","author":"Mittal","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00181","article-title":"Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors","volume":"6","author":"Kasi","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-025-00807-4","article-title":"Circulating tumor DNA profiling reveals genomic evolution in recurrent gastric or gastroesophageal junction cancer","volume":"29","author":"Kawabata","year":"2025","journal-title":"Mol Diagn Ther"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27992","article-title":"Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent\/metastatic head and neck squamous cell carcinoma","volume":"12","author":"Haring","year":"2021","journal-title":"Oncotarget"},{"key":"B164","doi-asserted-by":"publisher","first-page":"20252","DOI":"10.1038\/s41598-024-70887-5","article-title":"Longitudinal dynamics of circulating tumor DNA for treatment monitoring in patients with breast cancer recurrence","volume":"14","author":"Yoo","year":"2024","journal-title":"Sci Rep"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3660","article-title":"Minimal residual disease using a plasma-only circulating tumor DNA assay to predict recurrence of metastatic colorectal cancer following curative intent treatment","volume":"30","author":"Parikh","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B166","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00432-024-05997-8","article-title":"Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab","volume":"150","author":"Wang","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"8873","DOI":"10.3390\/ijms24108873","article-title":"Monitoring treatment response, early recurrence, and survival in uterine serous carcinoma and carcinosarcoma patients using personalized circulating tumor DNA biomarkers","volume":"24","author":"Bellone","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1177\/1010428320919198","article-title":"Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study","volume":"42","author":"Alves","year":"2020","journal-title":"Tumour Biol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"108810","DOI":"10.1016\/j.surg.2024.06.060","article-title":"Preoperative liquid biopsy for optimal patient selection in metastatic colorectal cancer","volume":"179","author":"Donica","year":"2025","journal-title":"Surgery"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70402","article-title":"Efficacy, safety, and biomarkers of neoadjuvant dalpiciclib (CDK4\/6 inhibitor) plus aromatase inhibitors in operable HER2-negative luminal B breast cancer: A prospective, single-center, single-arm, phase II trial (DANCER)","volume":"6","author":"Zhou","year":"2025","journal-title":"MedComm (2020)"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106067","article-title":"Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer","volume":"11","author":"Grinshpun","year":"2026","journal-title":"ESMO Open"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","article-title":"Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy","volume":"41","author":"Magbanua","year":"2023","journal-title":"Cancer Cell"},{"key":"B173","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41523-026-00934-z","article-title":"Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 trial","volume":"12","author":"Egle","year":"2026","journal-title":"NPJ Breast Cancer"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12366-7","article-title":"ctDNA for risk of recurrence assessment in patients treated with neoadjuvant treatment: A systematic review and meta-analysis","volume":"29","author":"G\u00f6genur","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003620","article-title":"Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study","volume":"18","author":"Tie","year":"2021","journal-title":"PloS Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.01.026","article-title":"Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer","volume":"49","author":"Hofste","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/SLA.0000000000006948","article-title":"Molecular residual disease and recurrence in rectal cancer patients undergoing upfront surgery: A prospective cohort study","volume":"283","author":"Ando","year":"2026","journal-title":"Ann Surg"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-04073-y","article-title":"Circulating tumor DNA as a predictive biomarker for colorectal cancer postsurgical recurrence: a systematic review and meta-analysis","volume":"28","author":"Khan","year":"2026","journal-title":"Clin Transl Oncol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.05.007","article-title":"Circulating tumor DNA as a biomarker of prognosis prediction in colorectal cancer: a systematic review and meta-analysis","volume":"5","author":"Zhou","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"B180","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12672-025-02220-z","article-title":"Circulating tumor DNA in colorectal cancer: biology, methods and applications","volume":"16","author":"Chen","year":"2025","journal-title":"Discov Oncol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27989","article-title":"Circulating tumor DNA as a marker of recurrence risk in stage III colorectal cancer: The \u03b1-CORRECT study","volume":"132","author":"Diergaarde","year":"2025","journal-title":"J Surg Oncol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.1093","article-title":"Evaluation of comparative surveillance strategies of circulating tumor DNA, imaging, and carcinoembryonic antigen levels in patients with resected colorectal cancer","volume":"5","author":"Fakih","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn441530-20250306-00087","article-title":"Interpretation of the update points of colorectal and anal cancer in CACA guidelines (2025 edition)","volume":"28","author":"Guan","year":"2025","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-22-616","article-title":"Molecular profiling and patient selection for the multimodal approaches for patients with resectable colorectal liver metastases","volume":"13","author":"Araujo","year":"2024","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn441530-20240613-00208","article-title":"Advances in the application of minimal residual disease in non-metastatic colorectal cancer","volume":"27","author":"Cao","year":"2024","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02660","article-title":"Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J Clin Oncol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-106","article-title":"Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients","volume":"11","author":"Yue","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.04.004","article-title":"Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer","volume":"10","author":"Abbosh","year":"2024","journal-title":"Trends Cancer"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-24-265","article-title":"Values of circulating tumor DNA for non-small cell lung cancer patients receiving neoadjuvant therapy, progress and challenges: a narrative review","volume":"16","author":"Zhou","year":"2024","journal-title":"J Thorac Dis"},{"key":"B190","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41392-023-01700-4","article-title":"Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112139-20240627-00315","article-title":"The significance and advancements of circulating tumor DNA in the diagnosis and treatment of operable non-small cell lung cancer","volume":"63","author":"Li","year":"2025","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101615","article-title":"Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE\/CTONG2104)","volume":"5","author":"Zhang","year":"2024","journal-title":"Cell Rep Med"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1629854","article-title":"Case report: Perioperative application of trastuzumab deruxtecan in HER2 exon 20 mutation-positive non-small cell lung cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100449","article-title":"Cancer in a drop: Liquid biopsy highlights from the World Conference on Lung Cancer (WCLC) 2025","volume":"10","author":"Ghazali","year":"2025","journal-title":"J Liq Biopsy"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1164543","article-title":"Complete pathological response and negative postoperative ctDNA were not predictive of discontinuation of adjuvant crizotinib therapy in a patient with locally advanced MET ex14 skipping mutation-positive non-small cell lung cancer: a case report","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvac121","article-title":"Circulating tumor DNA as a biomarker for monitoring patients with solid cancers: Comparison with standard protein biomarkers","volume":"68","author":"Duffy","year":"2022","journal-title":"Clin Chem"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1002\/biof.70095","article-title":"Is there an ace up one\u2019s sleeve in the preanalytical phase of the circulating tumor DNA analysis","volume":"52","author":"de Azevedo Junior","year":"2026","journal-title":"Biofactors"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2023.2230290","article-title":"Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis","volume":"60","author":"Ntzifa","year":"2023","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvad194","article-title":"Critical factors in the analytical work flow of circulating tumor DNA-based molecular profiling","volume":"70","author":"van der Leest","year":"2024","journal-title":"Clin Chem"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.1026","article-title":"Clinical circulating tumor DNA testing for precision oncology","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13156","article-title":"Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care","volume":"16","author":"Hedtke","year":"2022","journal-title":"Mol Oncol"},{"key":"B202","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3390\/cancers14030851","article-title":"Clinical validity of circulating tumor DNA as prognostic and predictive marker for personalized colorectal cancer patient management","volume":"14","author":"Hallermayr","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1089\/bio.2024.0083","article-title":"MIBLood-EV: An online reporting tool to facilitate the standardized reporting of preanalytical variables and quality control of plasma and serum to enhance rigor and reproducibility in liquid biopsy research","volume":"23","author":"Gustafson","year":"2025","journal-title":"Biopreserv Biobank"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2024.100147","article-title":"With >1000 authors, the updated \u201cMinimum Information for Studies of Extracellular Vesicles\u201d (MISEV) promotes rigor, reproducibility, and transparency in the liquid biopsy field","volume":"4","author":"Nadeau","year":"2024","journal-title":"J Liq Biopsy"},{"key":"B205","doi-asserted-by":"publisher","first-page":"103696","DOI":"10.1016\/j.jtho.2026.103696","article-title":"Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - a Delphi study by the Asian Thoracic Oncology Research Group (ATORG)","author":"Tan","year":"2026","journal-title":"J Thorac Oncol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"e005344","DOI":"10.1136\/jitc-2022-005344","article-title":"Regulatory implications of ctDNA in immuno-oncology for solid tumors","volume":"11","author":"Vellanki","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102362","article-title":"Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: a systematic review and meta-analysis","volume":"104","author":"Papakonstantinou","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00376","article-title":"Role of circulating tumor DNA tumor fraction in advanced non-small cell lung cancer and its impact on patient treatment outcomes: a prospective real-world study","volume":"9","author":"Cheung","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B210","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.3390\/cancers17172831","article-title":"Prognostic value of circulating tumor DNA in HR+\/HER2- stage I-III breast cancer: a systematic review","volume":"17","author":"Ajjawi","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B211","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.20892\/j.issn.2095-3941.2025.0431","article-title":"From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management","volume":"22","author":"Xu","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00372","article-title":"Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"6","author":"Vega","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2024.2302116","article-title":"Liquid biopsy for the management of NSCLC patients under osimertinib treatment","volume":"61","author":"Ntzifa","year":"2024","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2023.2228837","article-title":"Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: an institutional feasibility study","volume":"40","author":"Mangum","year":"2023","journal-title":"Pediatr Hematol Oncol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.657483","article-title":"Circulating tumor DNA analyses predict disease recurrence in non-muscle-invasive bladder cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1101\/2023.11.10.566658","article-title":"Modeling the effect of spatial structure on solid tumor evolution and ctDNA composition","author":"Rachman","year":"2023","journal-title":"bioRxiv"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02445-1","article-title":"Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors","volume":"129","author":"Thompson","year":"2023","journal-title":"Br J Cancer"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-2312","article-title":"Broad utility of ultrasensitive analysis of ctDNA dynamics across solid tumors treated with immunotherapy","volume":"32","author":"Garralda","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00148","article-title":"Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse","volume":"6","author":"Cailleux","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2025.06.008","article-title":"Analytical validation of blood-derived tumor mutation burden (bTMB) assays: a joint consensus recommendation of the BLOODPAC bTMB Analytical Validation Working Group","volume":"27","author":"Baden","year":"2025","journal-title":"J Mol Diagn"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2026.120865","article-title":"Circulating biomarkers in leukemia","volume":"584","author":"Dong","year":"2026","journal-title":"Clin Chim Acta"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1515\/almed-2025-0010","article-title":"Circulating tumor DNA in patients with cancer: insights from clinical laboratory","volume":"6","author":"Illana","year":"2025","journal-title":"Adv Lab Med"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1746","article-title":"Improved assessment of response status in patients with pancreatic cancer treated with neoadjuvant therapy using somatic mutations and liquid biopsy analysis","volume":"27","author":"Yin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2025.01142","article-title":"Exosome-based liquid biopsy: a new frontier in early cancer diagnosis","volume":"19","author":"Li","year":"2025","journal-title":"Biosci Trends"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17397-4","article-title":"Utilizing combined circulating tumor DNA and tumor markers to evaluate neoadjuvant therapy response and predict recurrence in patients with locally advanced gastric cancer","volume":"32","author":"Zhu","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033575","article-title":"Planning adaptive treatment by longitudinal response assessment implementing MR imaging, liquid biopsy and analysis of microenvironment during neoadjuvant treatment of rectal cancer (PRIMO)","volume":"102","author":"Wurschi","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.08.020","article-title":"Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"139","author":"Salvador-Coloma","year":"2020","journal-title":"Eur J Cancer"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-025-01818-z","article-title":"Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer","volume":"33","author":"Park","year":"2026","journal-title":"Breast Cancer"},{"key":"B229","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12885-024-11879-6","article-title":"An update of clinical value of circulating tumor DNA in esophageal cancer: a systematic review and meta-analysis","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"B230","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/SLA.0000000000006209","article-title":"Prospective evaluation of circulating tumor DNA using next-generation sequencing as a biomarker during neoadjuvant chemotherapy in localized pancreatic cancer","volume":"281","author":"Shah","year":"2025","journal-title":"Ann Surg"},{"key":"B231","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/j.cllc.2025.05.006","article-title":"KRAS ctDNA detection in patients with resectable lung adenocarcinoma","volume":"26","author":"De Meo","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-026-19539-8","article-title":"Potential of circulating tumor DNA in stratifying patients with localized pMMR colon cancer to neoadjuvant therapy","volume":"33","author":"Smith","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"B233","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12885-025-13526-0","article-title":"Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis","volume":"25","author":"Niu","year":"2025","journal-title":"BMC Cancer"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.pccm.2023.04.001","article-title":"Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer","volume":"1","author":"Tang","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.1282","article-title":"Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection","volume":"30","author":"Hata","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2022.06.009","article-title":"Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma","volume":"22","author":"Ueberroth","year":"2022","journal-title":"Pancreatology"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-2234","article-title":"Clinical validation of digital PCR-based ctDNA detection for risk stratification in residual triple-negative breast cancer: TRICIA trial results","volume":"32","author":"Roseshter","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B238","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clcc.2022.03.004","article-title":"The future of ctDNA-defined minimal residual disease: personalizing adjuvant therapy in colorectal cancer","volume":"21","author":"Bent","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-390","article-title":"Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review","volume":"11","author":"Verz\u00e8","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1242","article-title":"ctDNA longitudinal analysis during total neoadjuvant therapy and nonoperative management for locally advanced rectal cancer: a biomarker study from the NOMINATE trial","volume":"31","author":"Akiyoshi","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B241","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3390\/diagnostics10080550","article-title":"Personalized treatment selection and disease monitoring using circulating tumor DNA profiling in real-world cancer patient management","volume":"10","author":"Wehrle","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104776","article-title":"Cancer in a drop: advances in liquid biopsy in 2024","volume":"213","author":"Borea","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B243","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1200\/PO.20.00276","article-title":"ctDNA MRD detection and personalized oncogenomic analysis in oligometastatic colorectal cancer from plasma and urine","volume":"5","author":"Pellini","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-190523","article-title":"Utility of urinary ctDNA to monitoring minimal residual disease in early breast cancer patients","volume":"28","author":"Guan","year":"2020","journal-title":"Cancer biomark"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1909934\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:43:13Z","timestamp":1787744593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1909934\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":244,"alternative-id":["10.3389\/fonc.2026.1909934"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1909934","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1909934"}}